• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Do Antidepressants Work for Kids?

Do Antidepressants Work for Kids?

November 1, 2003
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.

What a bind we seem to be in.

On the one hand, we are short several thousand child psychiatrists in the United States, and parents are beating down our (generalist) doors to get their children medicated. On the other hand, every other piece of news about childhood psychopharmacology seems either bad or lukewarm.

In this issue, TCR takes a stab at sorting through one particularly controversial issue--the use of antidepressants in children and adolescents.

To begin with tricyclics (TCAs): while they are tremendously effective for adults with depression, they appear not to touch depressed kids, regardless of the dose. Studies using amitriptyline at 173 mg/day (Birmaher, JAACAP, 1998;37:527-535), desipramine 214 mg/day (Klein, Depress. Anxiety, 1998, 7:15-31), and more recently, imipramine 205 mg/day (Keller, JAACAP, 2001;40:762- 772), have all failed to show any difference between active TCA treatment and placebo in well-designed double blind, random assignment studies.
Prozac has won approval, but other good candidates are hard to find

Why such dismal performances? There is some interesting laboratory data indicating that the noradrenergic system is pretty immature at a young age, and that it therefore may be atypically unresponsive to medications that boost norepinephrine levels. However, a recently approved norepinephrine reuptake inhibitor, Straterra (see TCR 1:4) appears to be just as effective for kids as for adults, casting some doubt on this theory.

Nonetheless, there's not a lot of hand-wringing over this anti-TCA data, because many of us remember the unsettling reports in the 1990s of 8 sudden deaths in children taking TCAs, mostly desipramine. While the issue of causality is controversial, the bottom line is that you’d better be pretty darn cautious when prescribing TCAs to kids, and if there’s a reason to avoid the risks, so much the better!

What about the SSRI's? There have been a grand total of five published placebo-controlled trials of SSRIs in kids. Three involved Prozac, one involved Paxil, and the fifth involved Zoloft. The results are charted below.

Table: The Five Published Placebo-Controlled Studies on SSRIs in Kids (As of November 2003)

Table: The Five Published Placebo-Controlled Studies on SSRIs in Kids (As of November 2003)

As you can see, Prozac comes out looking pretty good, with two positive studies, which is why it is currently the only antidepressant approved by the FDA for children.

The one published study of Paxil showed a significant response rate, but when the outcome was the final average depression score, there was no separation from placebo. There are also three unpublished studies of Paxil for kids, all of which are being pored over by the FDA even as you read this. The results are available through your GlaxoSmithKline rep, and they are not impressive. These studies enrolled a total of 288 depressed children or adolescents in the Paxil arms, vs. 201 on placebo. There was nary a wisp of a difference between response to drug vs. placebo; in one study ("study 701"), there was actually a trend in favor of placebo.

The recent Zoloft study received plenty of good press, but a 69%/59% drug/placebo difference doesn’t spark a whole lot of enthusiasm, even if it is statistically significant.

Taken together, it is hard to shake the view that treating depression in kids with SSRIs is a dodgy proposition. The published results are uninspiring, and the unpublished results are downright abysmal.

But what about the other newer antidepressants?

Wellbutrin is safe to use for adolescents, which we know from successful studies of ADHD, but only one uncontrolled study has examined this for outpatient depression, in adolescents with both ADHD and depression or dysthymia (Daviss, JAACAP, 2001, 40:307-314.) Wellbutrin (average dose 4 mg/kg per day, in split dosing) resulted in a 62% response rate for ADHD and a robust 87% response rate for depression or dysthymia. Impressive numbers, but this was an open label study, in which placebo effects are impossible to separate from medication effects.

There have been placebo-controlled studies of Effexor, Serzone, and Remeron in kids, none of which have shown benefit over placebo.

The bottom-line seems to be that antidepressants are only marginally more effective than placebo when given to children and adolescents. Nonetheless, the only way we non-researcher clinicians can ethically engage this powerful placebo effect is by writing out prescriptions for real medications. What more can one say? Time to sharpen up your psychotherapy skills!

TCR VERDICT:
For Kids: First A Hope, then a Prayer, then an SSRI

1. Simeon JG, Dinicola VF, Ferguson HB, et al. (1990), Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. prog Neuropsychopharm Biol Psychiatry 14:791-795
2. Emslie GJ, Rush AJ, Weinberg WA et al. (1997), A double- blind, randomized, placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 54(11):1031-1037.
3. Emslie GJ, Heiligenstein JH, Wagner KD et al. (2002b), Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41(10):1205-1215.
4. Keller MB, Ryan ND, Strober M et al. (2001), Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry: 40(7):762-772.
5. Wagner KD, Ambrosini P, Rynn M, et al. (2003), Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA 290:1033-1041
General Psychiatry
KEYWORDS antidepressants child_psychiatry
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2003
    SUBSCRIBE NOW
    Table Of Contents
    Dr. Jeff Bostic on Treating Pediatric Depression
    Working with Family
    Watson and “Little Albert”
    How to Evaluate Adolescents
    Suicidality and SSRI’s: An Update
    Do Antidepressants Work for Kids?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.